Elite Pharmaceuticals (ELTP) Q4 2025 earnings summary

Executive summary

• Fiscal 2025 revenue reached $84 million, a 52% increase year-over-year, driven by the successful launch of lisdexamfetamine and growth in legacy products.

• Operating income rose to $19.6 million, up 82% from the prior year, marking another record year of profitability.

• The company has established a strong market presence, with significant market shares in key generic products and a robust product pipeline.

• Strategic priorities include potential M&A, Nasdaq uplisting, and continued R&D investment.

• Fiscal year ended March 31, 2025, saw significant revenue and profit growth driven by new product launches and expansion of existing product lines.

Financial highlights

• Revenue increased to $84 million from $56.6 million year-over-year, a $27.9 million or 52% rise.

• Operating income nearly doubled to $19.6 million from $10.8 million, an 82% increase.

• Cash flow from operations improved to +$7.5 million from a $3.2 million burn, a $10.7 million positive swing.

• Working capital rose to $45.9 million, up 41% from $27 million.

• EPS for 2025 was zero, down from $0.02 last year, due to a non-cash derivative expense.

Outlook and guidance

• Lisdexamfetamine expected to remain a key product with attractive margins as the generic market expands.

• Anticipated growth in amphetamine ER after Prasco's license ends and further market penetration in legacy and new products.

• Continued focus on M&A as the primary strategic objective, with Nasdaq uplisting as a secondary option.

• Management to discuss year-end results and recent business developments in a scheduled conference call.